TVM Capital Invests in Riemser Arzneimittel AG

Munich and Boston-based TVM Capital invested in Riemser
Arzneimittel AG effective December 27, 2007. Riemser Arzneimittel AG
is a midsized pharmaceutical company on the island Riems in
Mecklenburg-Vorpommern, Germany.

Riemser Arzneimittel AG, owned and controlled by the Braun Family,
has 450 employees at four manufacturing plants with annual revenues
(2006) of about 56 million Euro. The company develops and produces a
line of successful dermatology, cardiovascular and anti-inflammatory,
oncology and dental care pharmaceuticals.

TVM Capital holds 10% of the Riemser AG shares; supported by
current management under the leadership of Norbert Braun, TVM Capital
will help transition and grow Riemser Arzneimittel AG into an
international corporation. Dr. Christoph Schroeder, Partner of TVM
Capital and former management executive of BASF Pharma, will join the
board of directors. "TVM Capital has always been an active shareholder
in enterprises with a strong focus in the areas of life sciences and
pharmaceuticals", explains Dr. Helmut Schuhsler, Managing Partner of
the TVM Capital Life Sciences Team. "We offer excellent know-how.
After all, we have invested in more than 90 life sciences companies
since the mid-eighties. Our interest in a successful, mid-size
enterprise like Riemser Arzneimittel AG is a consistent and logical
development of our current investment strategy to invest in more
mature life sciences enterprises with interesting growth
perspectives."

"Our company is well established in its niche markets. Expanding
our investors to include an internationally renowned pharmaceutical
investor like TVM Capital, will enable Riemser Arzneimeittel AG to
grow internationally. TVM Capital will facilitate this process with
its multifaceted expertise and contacts. Our joint goal is to further
develop an already successful Riemser Arzneimittel AG and accelerate
the existing growth", says Norbert Braun, CEO of Riemser Arzneimittel
AG.

Additional editorial information:

RIEMSER Arzneimittel AG

RIEMSER Arzneimittel AG is a pharmaceutical company located on the
island of Riems, Germany. RIEMSER Arzneimittel AG operates several
companies in Germany, producing anti-inflammatory, dermatological and
dental drugs. Partners in research and development are renowned
research institutes and universities throughout Germany and Europe. In
the area of Mecklenburg-Vorpommern, the Medical Faculties Institute of
the University of Rostock and Greifswald as well as the renowned
Friedrich-Loeffler-Institute Insel Riems (FLI) serve as research
partners. Additional information: www.riemser.de

TVM Capital

TVM Capital, founded in 1983, is one of the first venture capital
firms formed in Germany and was an early entrant into the US market in
1986. Since inception, TVM Capital has raised more than EUR 1.3
billion in six fund generations and has established itself as a
leading international technology and life science investment group.
TVM Capital funds have made investments in more than 235 technology
and life science companies including emerging technology sectors such
as energy efficiency, renewable energy generation, energy storage and
water treatment. Over the life of the firm, TVM Capital has developed
specialized, focused teams and dedicated funds to serve high-growth
target markets. The TVM Capital investment strategy is to create
global businesses that enjoy worldwide access to science, technology,
management talent and capital, and to develop them into significant
players in their markets. More than 50 TVM Capital backed companies
have gone public on European or US stock exchanges. Today, TVM Capital
is actively invested in 70 companies. For more information please
visit: www.tvm-capital.com